Multiple Sclerosis Clinical Trial

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect

Summary

The study aims to evaluate MSCopilot®, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS).

The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution.

A secondary objective is to determine MSCopilot®'s ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients.

Exploratory objectives include evaluating the relationship between MSCopilot® composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL).

Patients will be able to download the free MSCopilot® app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression.

The study will include 243 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adult patients living with RRMS or SPMS, aged 30 to 65
EDSS score between 2.5 to 6.5 points
With a disease duration > 5 years
Clinically stable during the last 3 months before inclusion (no relapses, no disability progression)
No change in the DMT* during the last 3 months before inclusion
Receiving optimal symptomatic treatments at baseline (clinician's judgment)
Owns a personal smartphone which mobile operating system is above 14 for IOS (iPhone) and 8 for Android included with a good internet connexion
Able to use a smartphone
Able to read language in wich the mobile application is available and able to understand pictograms.
Applicable to patients enrolled in France only: affiliated to a social security system.

Exclusion Criteria:

Medically unstable conditions that may hinder patient's ability to comply with the study procedures
Inability to use a smartphone or MSCopilot® Detect application
Patient with corrected visual acuity less than 4/10 (Monoyer) or 20/50 (Snellen at 20 feet) or +0,4 (LogMAR)
Pregnancy and nursing women
Persons under guardianship or curatorship
Current drugs or/and alcohol abuse that could influence performance on the tests (clinician's judgment)
Patients have participated in another clinical study within the previous 30 days of screening or are currently participating in another study that, in the opinion of the Investigator, might interfere with the patient's full participation in the study or confound the assessment of the patient or outcome of the study.

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

314

Study ID:

NCT05816122

Recruitment Status:

Recruiting

Sponsor:

Ad scientiam

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Joash Lazarus Sr.
Atlanta Georgia, 30327, United States More Info
Joash Lazarus, Dr
Contact
404-351-0205
[email protected]
Craig E. Herrman
Indianapolis Indiana, 46256, United States More Info
Craig Herrman, Dr
Contact
317-639-3528
[email protected]
Aaron Boster
Columbus Ohio, 43235, United States More Info
Aaron Boster, Dr
Contact
614-304-3444
[email protected]
Gabriel Pardo
Oklahoma City Oklahoma, 73104, United States More Info
Gabriel Pardo, Dr.
Contact
405-271-6242
[email protected]
Galina Vorobeychik
Burnaby , , Canada More Info
Galina Vorobeychik, Dr
Contact
[email protected]
Mark Freedman
Ottawa , , Canada More Info
Mark Freedman, Dr
Contact
[email protected]
St. Michael's Hospital
Toronto , , Canada More Info
Jiwon Oh, Prof.
Contact
[email protected]
Robert Carruthers
Vancouver , , Canada More Info
Robert Carruthers, Dr
Contact
[email protected]
University Hospital of Southern Denmark
Esbjerg , , Denmark More Info
Tobias Sejbaek, Dr.
Contact
[email protected]
Helene Hoejsgaard Chow
Glostrup , , Denmark More Info
Helene Hoejsgaard Chow, Dr
Contact
[email protected]
Henrik Boye Jensen
Kolding , , Denmark More Info
Hentik Boye Jensen, Dr
Contact
[email protected]
Sivagini Prakash
Viborg , , Denmark More Info
Sivagini Prakash, Dr
Contact
[email protected]
Hôpital Roger Salengro
Lille , , France More Info
Patrick Vermersch, Prof.
Contact
[email protected]
Cécile Donzé
Lomme , , France More Info
Cécile Donzé, Dr
Contact
[email protected]
Adil Maarouf
Marseille , , France More Info
Adil Maarouf, Dr
Contact
[email protected]
Mikael Cohen
Nice , , France More Info
Mikael Cohen, Dr
Contact
[email protected]
Bertrand Bourre
Rouen , , France More Info
Bertrand Bourre, Dr
Contact
[email protected]
Boris-Alexander Kallman
Bayreuth , , Germany More Info
Boris-Alexander Kallman, Dr
Contact
[email protected]
Felix Bischof
Böblingen , , Germany More Info
Felix Bischof, Dr
Contact
[email protected]
Universitätsklinikum Carl Gustav Carus
Dresden , , Germany More Info
Tjalf Ziemssen, Prof.
Contact
[email protected]
Rupert Knoblich
Erbach , , Germany More Info
Rupert Knoblich, Dr
Contact
[email protected]
Damiano Paolicelli
Bari , , Italy More Info
Damiano Paolicelli, Dr
Contact
[email protected]
Emilio Portaccio
Florence , , Italy More Info
Emilio Portaccio, Dr
Contact
[email protected]
Emanuele D'Amico
Foggia , , Italy More Info
Emanuele D'Amico, Dr
Contact
[email protected]
IRCCS Ospedale San Raffaele
Milan , , Italy More Info
Massimo Filippi, Prof.
Contact
[email protected]
Carla Tortorella
Roma , , Italy More Info
Carla Tortorella, Dr
Contact
[email protected]
Lluís Ramió
Girona , , Spain More Info
Lluís Ramió, Dr
Contact
[email protected]
Enric Monreal
Madrid , , Spain More Info
Enric Monreal, Dr
Contact
[email protected]
University Hospital San Carlos
Madrid , , Spain More Info
Celia Oreja-Guevara, Prof.
Contact
[email protected]
Ana Alonso
Málaga , , Spain More Info
Ana Alonso, Dr
Contact
[email protected]
Miguel Llaneza
Oviedo , , Spain More Info
Miguel Llaneza, Dr
Contact
[email protected]
Jesùs Martin
Zaragoza , , Spain More Info
Jesùs Martin, Dr
Contact
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

314

Study ID:

NCT05816122

Recruitment Status:

Recruiting

Sponsor:


Ad scientiam

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.